

RECEIVED

APR 25 2001

TECHNOLOGY 9:266-2900
EXHIBIT 1600/2900

(11) Exhibit K, a copy of Tempest *et al.*, 1995, Int. J. Biol. Macromol.

17:37-42;

(12) Exhibit L, a copy of Tempest *et al.*, 1991, Bio/Technology

(13) Exhibit M, a copy of Tempest *et al.*, 1994, Protein Eng. 7:1501-1507;

(14) Exhibit N, a copy of Tempest *et al.*, 1994, Hybridoma 13:183-190;

(15) Exhibit O, a copy of Graziano *et al.*, 1995, J. Immunology

155:4996-5002;

(16) Exhibit P, a copy of U.S. Patent No. 5,585,089 to Queen;

(17) Exhibit Q, a sequence alignment of the heavy and light chain variable regions of the anti-CD40 antibodies 5D12, humanized 5D12, and S2C6;

(18) Exhibit R, a copy of Uckun *et al.*, 1990, Blood 76:2449-2456;

(19) a Petition Under 37 C.F.R. § 1.136(a) for an Extension of Time to Respond for three months up to and including April 18, 2001, plus the necessary fee;

(20) an Amendment Fee Transmittal Sheet, with the necessary fee; and

(21) a Second Supplemental Information Disclosure Statement, with a List of References Cited and copies of references BK-BO, together the necessary fee.

IN THE SPECIFICATION:

On page ii, line 19, please replace the following Table of Contents section "10. DEPOSIT OF MICROORGANISM 58" with the following Table of Contents section:

a 10. DEPOSIT OF HYBRIDOMA 58

On page 24-25, please replace the paragraph beginning "For preparation of additional monoclonal antibodies to CD40" with the following paragraph:

For preparation of additional monoclonal antibodies to CD40, any technique that provides for the production of antibody molecules by continuous cell lines in culture may be used. These include but are not limited to the hybridoma technique of Kohler and Milstein, (1975, Nature 256, 495-497; and U.S. Patent No. 4,376,110), the human B-cell hybridoma technique (Kozbor *et al.*, 1983, Immunology Today 4, 72; Cole *et al.*, 1983, Proc. Natl. Acad. Sci. USA 80, 2026-2030), and the EBV-hybridoma technique to produce human monoclonal antibodies (Cole *et al.*, 1985, Monoclonal Antibodies And Cancer Therapy, Alan R. Liss, Inc., pp. 77-96). Such antibodies or other anti-CD40 antibodies